Core Viewpoint - The company has submitted a registration application for its self-developed 13-valent pneumococcal conjugate vaccine to the National Medical Products Administration on October 31, indicating a significant step towards market entry and addressing supply gaps in the global market [1] Company Summary - The 13-valent pneumococcal conjugate vaccine was previously a global sales champion before the COVID-19 pandemic, demonstrating its strong market potential [1] - Phase III clinical studies have shown that the vaccine possesses good immunogenicity and safety [1] - The launch of this vaccine is expected to significantly enhance the company's performance by filling the supply gap in the global market for 13-valent pneumococcal vaccines [1] Industry Summary - According to the World Health Organization, pneumococcal diseases are among the prioritized diseases for vaccine prevention, highlighting the importance of this vaccine in public health [1] - Pfizer's similar vaccine achieved global sales of $6.44 billion in 2023, indicating strong market demand for pneumococcal vaccines [1] - The vaccine penetration rate in China is relatively low, with market sales reaching approximately 9.5 billion RMB in 2022, projected to grow to 35 billion RMB by 2030 [1]
艾美疫苗：13价结合肺炎疫苗已提交上市注册申请